What's in Fujian Shengdi Pharmaceutical Co., Ltd.'s pipeline?

Fujian Shengdi Pharmaceutical Co., Ltd. has 19 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 8 in Phase 2, 7 in Phase 1.

Which companies overlap with Fujian Shengdi Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: University of British Columbia, Hoffmann-La Roche, Merck Sharp & Dohme LLC, Sanofi, AceLink Therapeutics, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fujian-shengdi-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fujian Shengdi Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fujian Shengdi Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 4 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 8 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
HRS9531 Tablet	HRS9531 Tablet	phase 3
HR19006	HR19006	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
All-in-one parenteral nutrition	All-in-one parenteral nutrition	phase 3	Parenteral nutrition formulation		Nutrition support / Critical care
HR20013 for injection；dexamethasone	HR20013 for injection；dexamethasone	phase 3	Glucocorticoid (corticosteroid)	Glucocorticoid receptor (GR)	Immunology / Inflammation

Therapeutic area mix

Diabetes · 1
Immunology / Inflammation · 1
Nutrition support / Critical care · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University of British Columbia · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Sanofi · 2 shared drug classes
AceLink Therapeutics, Inc. · 1 shared drug class
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
AJU Pharm Co., Ltd. · 1 shared drug class
Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fujian Shengdi Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Fujian Shengdi Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fujian-shengdi-pharmaceutical-co-ltd. Accessed 2026-05-17.